Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160276 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2 | |
| SCHEMBL12332643 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTBLMLMNAKMT2A | |
| SCHEMBL16524045 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL627520 | 0.77 | MAPK1 (0.57) | SMN1; SMN2MAPTLMNAGAA | |
| SCHEMBL21964602 | 0.74 | ALPL (0.47) | MAPTKMT2AALDH1A1 | |
| SCHEMBL17796561 | 0.74 | MAPT (0.58) | SMN1; SMN2MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL14917715 | 0.73 | MAPK1 (0.34) | SMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL3932634 | 0.73 | MAPK8 (0.55) | SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL18529294 | 0.72 | — | — | |
| SCHEMBL10399828 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200296-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (HK) | 2023-06-28 | — | — | EP | disclosed |
| CN-112939948-B | Novel quinazoline-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022038563-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (CN) | 2022-02-24 | — | — | WO | disclosed |
| WO-2021115432-A1 | NOVEL QUINAZOLINE-CONTAINING COMPOUND, AND INTERMEDIATE THEREOF AND USE THEREOF | 苏州长禾药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-112939948-A | Novel quinazoline-containing compound, intermediate and application thereof | 苏州长禾药业股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-105601619-A | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP | 2016-05-25 | — | — | CN | disclosed |
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | disclosed |
| EP-2611502-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102395576-A | Quinazoline derivatives that modulate JAK kinases and methods of use thereof | AMBIT BIOSCIENCES CORP | 2012-03-28 | — | — | CN | disclosed |
| WO-2012030918-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | SMN1; SMN2 2798/4885CYP3A4 3115/4885PLA2G10 3776/4885 |
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | SMN1; SMN2 360/4885CYP3A4 4455/4885PLA2G10 3222/4885 |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | SMN1; SMN2 4351/4885CYP3A4 3372/4885PLA2G10 2559/4885 |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | SMN1; SMN2 2798/4885CYP3A4 3115/4885PLA2G10 3776/4885 |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4779/4885CYP3A4 2890/4885PLA2G10 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.